Evidence map›Paper›PMID 26240335›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

C-S bond cleavage by a polyketide synthase domain.

Ming Ma, Jeremy R Lohman, Tao Liu, Ben Shen

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Discovery of the leinamycin family of natural products by mining actinobacterial genomes.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  17. Review
  18. Article
  19. Article
  20. Harnessing natural product assembly lines: structure, promiscuity, and engineering.Journal of industrial microbiology & biotechnology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ming MaDepartment of Chemistry, The Scripps Research Institute, Jupiter, FL 33458;
Jeremy R LohmanDepartment of Chemistry, The Scripps Research Institute, Jupiter, FL 33458;
Tao LiuDivision of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, WI 53705;
Ben ShenDepartment of Chemistry, The Scripps Research Institute, Jupiter, FL 33458; Division of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, WI 53705; Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL 33458; Natural Products Library Initiative at The Scripps Research Institute, The Scripps Research Institute, Jupiter, FL 33458 shenb@scripps.edu.

Funding

AT-less Type I Polyketide SynthasesR01CA106150 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SHEN, BEN · 2004 to 2015
$3.3M
NCI NIH HHS CA106150NCI NIH HHS R01 CA106150
6 · The paper itself

Abstract

Leinamycin (LNM) is a sulfur-containing antitumor antibiotic featuring an unusual 1,3-dioxo-1,2-dithiolane moiety that is spiro-fused to a thiazole-containing 18-membered lactam ring. The 1,3-dioxo-1,2-dithiolane moiety is essential for LNM's antitumor activity, by virtue of its ability to generate an episulfonium ion intermediate capable of alkylating DNA. We have previously cloned and sequenced the lnm gene cluster from Streptomyces atroolivaceus S-140. In vivo and in vitro characterizations of the LNM biosynthetic machinery have since established that: (i) the 18-membered macrolactam backbone is synthesized by LnmP, LnmQ, LnmJ, LnmI, and LnmG, (ii) the alkyl branch at C-3 of LNM is installed by LnmK, LnmL, LnmM, and LnmF, and (iii) leinamycin E1 (LNM E1), bearing a thiol moiety at C-3, is the nascent product of the LNM hybrid nonribosomal peptide synthetase (NRPS)-acyltransferase (AT)-less type I polyketide synthase (PKS). Sulfur incorporation at C-3 of LNM E1, however, has not been addressed. Here we report that: (i) the bioinformatics analysis reveals a pyridoxal phosphate (PLP)-dependent domain, we termed cysteine lyase (SH) domain (LnmJ-SH), within PKS module-8 of LnmJ; (ii) the LnmJ-SH domain catalyzes C-S bond cleavage by using l-cysteine and l-cysteine S-modified analogs as substrates through a PLP-dependent β-elimination reaction, establishing l-cysteine as the origin of sulfur at C-3 of LNM; and (iii) the LnmJ-SH domain, sharing no sequence homology with any other enzymes catalyzing C-S bond cleavage, represents a new family of PKS domains that expands the chemistry and enzymology of PKSs and might be exploited to incorporate sulfur into polyketide natural products by PKS engineering.

Indexed as

Antibiotics, AntineoplasticCarbonCarbon-Sulfur LyasesComputational BiologyCysteineDrug DesignLactamsMacrolidesMultigene FamilyPhylogenyPolyketidesPolyketide SynthasesProtein EngineeringProtein Structure, TertiaryStreptomycesSubstrate SpecificityAntibiotics, AntineoplasticCarbonCarbon-Sulfur LyasesCysteinecysteine lyaseLactamsleinamycinMacrolidesPolyketidesPolyketide SynthasesSulfhydryl CompoundsSulfidesThiazolesThionescysteine metabolismenzyme mechanismgenome miningpathway engineeringsulfur metabolism

Identifiers

PMID26240335
PMCPMC4547226

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.